PATIENT PREFERENCES FOR ATTRIBUTES OF BISPECIFIC ANTIBODIES INDICATED FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES